Citius Oncology, Inc. (CTOR) Earnings History
Annual and quarterly earnings data from 2022 to 2025
Loading earnings history...
CTOR EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CTOR Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
Download Data
Export CTOR earnings history in CSV or JSON format
Free sign-in required to download data
Citius Oncology, Inc. (CTOR) Earnings Overview
As of May 8, 2026, Citius Oncology, Inc. (CTOR) reported trailing twelve-month net income of -$25M, reflecting -13.3% year-over-year growth. The company earned $-0.31 per diluted share over the past four quarters.
Looking at the long-term picture, CTOR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2022.
Citius Oncology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including HALO ($317M net income, 22.7% margin), NKTR (-$164M net income, -297.1% margin), ADMA ($165M net income, 28.8% margin), CTOR has comparable earnings metrics. Compare CTOR vs HALO →
CTOR Earnings vs Peers
Earnings metrics vs comparable public companies
CTOR Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$25M | -17.1% | -$24M | $-0.34 | - | - |
| 2024 | -$21M | -66.6% | -$21M | $-0.30 | - | - |
| 2023 | -$13M | -133.7% | -$12M | $-0.19 | - | - |
| 2022 | -$5M | - | -$5M | $-0.08 | - | - |
See CTOR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTOR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTOR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTOR — Frequently Asked Questions
Quick answers to the most common questions about buying CTOR stock.
Is CTOR growing earnings?
CTOR EPS fell to $-0.31, with earnings declining -13.3%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-25M.
What are CTOR's profit margins?
Citius Oncology, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CTOR's earnings?
CTOR earnings data spans 2022-2025. The declining earnings trend is -13.3% YoY. Historical data enables comparison across business cycles.